Inadequate Warnings Expand Onglyza MDL
Inadequate Warnings Expand Onglyza MDL
Introduction
A growing number of Onglyza lawsuits are fast becoming a part of MDL No. 2809 established in February for coordinated pretrial proceedings. AstraZeneca and Bristol Myers Squibb are the defendants named in this litigation. Cases have been coordinated in the U.S. District Court for the Eastern District of Kentucky under District Judge Karen K. Caldwell.
Recently, a lawsuit was filed in the U.S. District Court for the Eastern District of Kentucky by a plaintiff, who claims that the use of Onglyza and Kombiglyze XR led to the development of his heart failure and other related injuries, which could have been avoided if the drug makers had provided adequate warnings. His claim also details how the defendants continued to market Onglyza and Kombiglyze XR as safe and effective, in spite of being well aware of the heart failure risks.
Comments
Latest News
Study Finds Toxic Metals in E-Cigs and U-Cigs Vapors
Categories: E-Cigarette: JUUL
As health concerns about e-cigarette use escalate, emerging research suggests that a newer class of vaping products—ultrasonic cigarettes or u-cigarettes—may pose even greater risks.
A study published in Environmental Health Perspectives in…
Appeals Court Upholds $611M Roundup Verdict
Categories: Roundup
A Missouri appeals court has upheld a massive Roundup verdict originally totaling $1.5 billion, but significantly reduced the final amount Bayer and its Monsanto unit must pay to $611 million.
The case involved three plaintiffs from New…
Valsartan “Wave 2” Bellwether Trial Schedule Set by Court
Categories: Valsartan
As the first Valsartan bellwether trial approaches in September 2025, the federal judge overseeing the multidistrict litigation (MDL) is preparing a second set of trials.
This move comes in anticipation of the possibility that parties may…